Marshall Wace, LLP Ikena Oncology, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding IKNA
# of Institutions
48Shares Held
33.8MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$5.87 Million1.88% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$4.79 Million2.71% of portfolio
-
Bvf Inc San Francisco, CA4.01MShares$4.69 Million0.23% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.71MShares$4.34 Million3.84% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$4.14 Million0.14% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $42.4M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...